What is Roka Bioscience?
Roka Bioscience, Inc. is a molecular diagnostics company headquartered in Warren, New Jersey, dedicated to the development and commercialization of advanced molecular assay technologies for the detection of foodborne pathogens within the United States. The company's flagship product, the Atlas instrument, is a fully automated molecular diagnostic testing platform designed to streamline laboratory workflows by automating all aspects of molecular diagnostic testing on a single, integrated system, thereby eliminating the need for batch processing. Roka Bioscience also offers a suite of Atlas detection assays targeting critical pathogens such as Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E.coli, and Listeria monocytogenes, alongside related consumable supplies. Its client base includes food processors, third-party contract testing laboratories, and government regulatory authorities, highlighting its role in ensuring food safety and public health.
How much funding has Roka Bioscience raised?
Roka Bioscience has raised a total of $150M across 4 funding rounds:
Series C
$20M
Series D
$47.5M
Stock Offering
$60M
Share Placement
$22.5M
Series C (2011): $20M with participation from Gen-Probe, New Enterprise Associates, OrbiMed, and TPG Biotech
Series D (2012): $47.5M led by OrbiMed, TPG Biotech, Aisling Capital, and New Enterprise Associates
Stock Issuance/Offering (2014): $60M, investors not publicly disclosed
Share Placement (2016): $22.5M, investors not publicly disclosed
Key Investors in Roka Bioscience
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with a deep focus on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They bring extensive experience in life sciences and healthcare business development, supporting companies from early-stage ventures to established organizations.
TPG Biotech
TPG Biotech is a global investment firm that manages alternative assets and supports business growth across diverse industries, including healthcare. They are known for their collaborative approach, combining sector expertise with strategic insight to identify opportunities and build long-term value in the life sciences sector.
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies developing and commercializing innovative healthcare products, services, and technologies, with a particular focus on biopharmaceutical development and commercial outsourcing services.
What's next for Roka Bioscience?
The substantial enterprise-level funding Roka Bioscience has attracted positions the company for significant scaling and further innovation in the competitive molecular diagnostics market. With a focus on automating pathogen detection, the company is well-placed to capitalize on the increasing demand for rapid and accurate diagnostic solutions in the food industry and beyond. Future strategic initiatives are likely to involve expanding its assay portfolio, enhancing the capabilities of the Atlas instrument, and broadening its market reach both domestically and internationally. Continued investment in research and development will be crucial for maintaining its technological edge and addressing emerging threats in food safety.
See full Roka Bioscience company page
